Prosight Management, LP Lipocine Inc. Transaction History

Prosight Management, LP

  • $372 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 14, 2018
SELL
$1.18 - $3.46 $440,259 - $1.29 Million
-373,101 Closed
0 $0
Q4 2017

Feb 13, 2018
BUY
$3.36 - $4.35 $1.25 Million - $1.62 Million
373,101
373,101 $1.28 Million

About Lipocine Inc.

LPCN Quotes by TradingView
  • Ticker LPCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,510,800
  • Market Cap $459M
  • Description
  • Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...
More about LPCN
Track This Portfolio

Track Prosight Management, LP Portfolio

Follow Prosight Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Prosight Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email